Skip to content

To compare the visual outcomes between EYECRYL lens and RAYNER EMV/HOYA IOL in cataract surgery patients

A Prospective, randomized, controlled, post-marketing clinical study to assess clinical performance and safety of EYECRYL Sert intraocular lens (IOL) versus RAYNER EMV/HOYA Impress IOL in patients with planned age-related cataract surgery. - nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068297
Enrollment
30
Registered
2024-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: H259- Unspecified age-related cataract

Interventions

Intervention1: EYECRYL Sert intraocular lens Intraocular Lens: Preloaded monofocal Hydrophobic Aspheric EDOF (Extended depth of focus) lens will be placed during cataract surgery and patients will be

Sponsors

BIOTECH VISION CARE PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (1) Patients having cataract (2) Potential postoperative BCDVA of 0.2 logMAR (20/32 Snellen) or better in each eye based on Investigator’s medical opinion

Exclusion criteria

Exclusion criteria: (1) Systemic disease that could increase the operative risk or confound the outcome; (2) instability of keratometry or biometry measurements; and (3) irregular astigmatism. (4) Systemic medications that may confound the outcome or increase the risk to the subject in the opinion of the investigator (tamsulosin hydrochloride (Flomax) or other medications with similar side effects (floppy iris syndrome)); (5) Ocular condition that may predispose for future complications (6) Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject; (7) Pregnant, lactating during the course of the investigation, or has another condition with associated fluctuation of hormones that could lead to refractive changes; (8) Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause future acuity loss to 20/30 or worse (9) Subjects with conditions that increase the risk of zonular rupture during cataract extraction procedure that may affect the postoperative centration or tilt of the lens; (10) If preclinical testing or risk analysis indicates potential for substantially increased light scatter over a monofocal lens, then exclude subjects who are expected to require retinal laser treatment; (11) Concurrent participation in another drug or device study

Design outcomes

Primary

MeasureTime frame
1.Distance Corrected Intermediate Monocular Visual Acuity at 66cm (DCIVA@66cm) under photopic light conditions (Mean Monocular DCIVA@66cmTimepoint: 180 days

Secondary

MeasureTime frame
1. In the study group, 50% of eyes achieving photopic monocular Distance Corrected Intermediate Visual Acuity (DCIVA) 0.2 logMAR or better @66 cmTimepoint: 120-180 days

Countries

India

Contacts

Public ContactDr Namrata Sharma

AIIMS, New Delhi

namrata.sharma@gmail.com9810856988

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026